Last reviewed · How we verify
Remsima SC
At a glance
| Generic name | Remsima SC |
|---|---|
| Sponsor | Celltrion |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
- A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
- Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD (NA)
- A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
- REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remsima SC CI brief — competitive landscape report
- Remsima SC updates RSS · CI watch RSS
- Celltrion portfolio CI